Fresenius Medical Care AG

RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
  • Ticker578580
  • ISINDE0005785802
  • SectorHealth Care Equipment & Services
  • CountryGermany

Analysts

Nurhayati Wan

Fresenius Medical Care

Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care sells Sound Inpatient Physicians for $2.15 billion, a credit positive

Proceeds from the disposal will improve Fresenius Medical Care's liquidity profile, diminish leverage and provide funds to pay for its acquisition of NxStage (announced in 2017).

Fresenius Medical Care AG & Co. KGaA: The sales of Sound Impatient Physicians for $2.15 billion is credit positive

Sound Impatient Physicians sale will reduce leverage and improve liquidity of Fresenius Medical Care.

FMC's Debt-Financed Acquisition of NxStage Medical Is Credit Negative

    ISSUER COMMENT  CORPORATES    AUGUST 10, 2017    FMC’s Debt-Financed Acquisition of NxStage  Medical Is Credit Negative  From  Credit Outlook   On Monday,  Fresenius Medical Care AG & Co. KGaA  (FMC, Baa3 stable) announced that

Fresenius Medical Care AG & Co. KGaA: FMC acquires NxStage Medical in sound strategic move; modest uptick in leverage towards the end of the Baa3 rating band

CORPORATES ISSUER COMMENT 8 August 2017 Contacts Stanislas Duquesnoy 49-69-70730-781 VP-Sr Credit Officer [email protected] Taisiia Alieksieienko 49-69-70730-707 Associate Analyst [email protected] Anke Rindermann 49-69-70730-788 Associate Managing Director [email protected] CLIENT SERVICES Americas 1-212-553-1653 Asia Pacific 852-3551-3077 Japan 81-3-5408-4100

Fresenius Medical Care AG & Co. KGaA: FMC successfully releases guarantees under secured facilities, a credit positive and supporting its Baa3 rating

CORPORATES ISSUER COMMENT 12 July 2017 Contacts Stanislas Duquesnoy 49-69-70730-781 VP-Sr Credit Officer [email protected] Anke Rindermann 49-69-70730-788 Associate Managing Director [email protected] Taisiia Alieksieienko 49-69-70730-707 Associate Analyst [email protected] Fresenius Medical Care AG & Co. KGaA FMC successfully releases guarantees under secu

Jake Strole

Morningstar | Trump Administration Proposes Changes to Dialysis Reimbursement

On July 10, President Donald Trump signed an executive order focused on improving kidney health for Americans. In tandem, the Centers for Medicare and Medicaid Services proposed four new payment models that will govern dialysis reimbursement through mid-2026. Three of the programs are voluntary and are effectively an extension and expansion of the existing Comprehensive ESRD Care Model that was set to run through 2020. More importantly, the mandatory ESRD Treatment Choices Model, or ETC, brings a sweeping incentive program that intends to cover half of all Medicare-enrolled ESRD beneficiaries ...

Jake Strole

Trump Administration Proposes Changes to Dialysis Reimbursement

On July 10, President Donald Trump signed an executive order focused on improving kidney health for Americans. In tandem, the Centers for Medicare and Medicaid Services proposed four new payment models that will govern dialysis reimbursement through mid-2026. Three of the programs are voluntary and are effectively an extension and expansion of the existing Comprehensive ESRD Care Model that was set to run through 2020. More importantly, the mandatory ESRD Treatment Choices Model, or ETC, brings ...

Jake Strole

Morningstar | DaVita's 1Q Weaker Than Expected, but Shares Remain Attractive

Narrow-moat DaVita posted first-quarter results that came in modestly below our expectations, but the firm appears on track to meet our outlook for the full year. The underlying source of weakness was same-facility treatment growth, which continued to decelerate to 2.4% from 2.6% in the fourth quarter of 2018. Both figures are the lowest we've seen in some time and stand in stark contrast to the 3.3% and 3.0% rates from Fresenius Medical Care's North American segment during the same periods. While these metrics aren't perfectly comparable, we find it notable that Fresenius has outgrown DaVita ...

Jake Strole

DaVita's 1Q Weaker Than Expected, but Shares Remain Attractive

Narrow-moat DaVita posted first-quarter results that came in modestly below our expectations, but the firm appears on track to meet our outlook for the full year. The underlying source of weakness was same-facility treatment growth, which continued to decelerate to 2.4% from 2.6% in the fourth quarter of 2018. Both figures are the lowest we've seen in some time and stand in stark contrast to the 3.3% and 3.0% rates from Fresenius Medical Care's North American segment during the same periods. Whi...

Jake Strole

Morningstar | Strong Start for Fresenius Medical Care Bodes Well for Dialysis Providers

Fresenius Medical Care reported a first quarter that fell within our expectations. We're encouraged that the firm is beginning the year tracking well against its full-year outlook following a tumultuous 2018. As we update our model, we don't intend to change our fair value estimate of EUR 82 per share ($47 per ADR) for this narrow-moat franchise. With shares beginning to more convincingly converge on fair value, we'd highlight peer DaVita as an alternative investment opportunity in the space trading at a much steeper discount to our valuation. There's not a lot to dislike in Fresenius' result...

1 director bought

A director at Fresenius Medical Care Ag & Co.Kgaa bought 2,425 shares at 68.642EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/14/2018

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/12/2018

...

Ahmed Ben Salem ...
  • Benoit Valleaux
  • Bruno Cavalier
  • Igor Kim
  • Jean Sassus
  • Jerôme Bodin
  • Johanna Jourdain
  • Matthias Desmarais
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/10/2018

...

Ahmed Ben Salem ...
  • Benoit Valleaux
  • Bruno Cavalier
  • Igor Kim
  • Jean Sassus
  • Jerôme Bodin
  • Johanna Jourdain
  • Matthias Desmarais
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 10/12/2018

...

Ahmed Ben Salem ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Igor Kim
  • Jean Sassus
  • Jean-Baptiste Rouphael
  • Martial Descoutures
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould
  • Valentin Pernet
  • Yan Derocles
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/01/2018

...

Nurhayati Wan

Fresenius Medical Care

FRESENIUS MED.CARE AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of FRESENIUS MED.CARE AG (DE), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date July 2, 2019, the closing price was EUR 70.44 and its potential was estimated at EUR 81.26.

Nurhayati Wan

Fresenius Medical Care

Nurhayati Wan

Fresenius Medical Care

Nurhayati Wan

Fresenius Medical Care

Carole Braudeau

Accor : Credit Feedback – Oddo BHF Forum 10 and 11 January

Our annual Forum in Lyon brought together 263 companies, including 41% of foreign companies, nearly 545 investors (33% foreigners), almost 6,500 one-to-one meetings. - This document gathers a brief feedback from the bond issuers and CB underlying companies in attendance. - - - - >Investment Grade - Accorhotels, Aéroports de Paris, Arkema, Buzzi Unicem, Carmila, Coface, Easyjet, Edenred, Fresenius Medical Care, Grand City Properties, Icade, JCDecaux, Klépierre, Lanxess, MT...

Carole Braudeau

Accor : Feedback Crédit Forum des 10 et 11 janvier 2019

Notre Forum annuel Oddo BHF 2019 vient de se dérouler à Lyon : il a réuni 263 sociétés, dont 41% étrangères, près de 545 investisseurs (33% étrangers), soit près de 6 500 one-to-one. - Ce document synthétise nos feed-back concernant les émetteurs obligataires présents et sous-jacents d’obligations convertibles. - - - >Investment Grade - Accorhotels, Aéroports de Paris, Arkema, Buzzi Unicem, Carmila, Coface, Easyjet, Edenred, Fresenius Medical Care, Grand City Properties,...

ValuEngine Sector Report for Medical

ValuEngine Sector Report for Medical

ValuEngine Sector Report for Medical

ValuEngine Sector Report for Medical

ValuEngine Sector Report for Medical

ValuEngine Sector Report for Medical

Expert Corporate Governance Service (ECGS)

Fresenius Medical Care AG & Co. KGaA - AGM 16 May 2019

Item 1: Unlike at German stock corporations, shareholders of a KGaA are legally required to vote on the annual accounts. Item 5a: KPMG has audited the Company since the financial year 1996 which exceeds our maximum acceptable term of office of 10 years or 20 years in cases where an audit tender has taken place after the initial engagement period. We consider a longer term of office may impair the auditor's independence. We welcome however that the Company has announced to change the audit firm as of financial year 2020, see item 5b of the agenda, and therefore exceptionally recommend to suppo...

Fresenius – Proxinvest Corporate Governance Rating ® : D

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Valérie GASTALDY

Analyse court terme - FRESENIUS MEDICAL CARE AG & CO KGAA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 68,35 €, puis 65,59 €. Le franchissement de 86,00 € remettrait en cause la suite de la baisse.

Valérie GASTALDY

Short term view - FRESENIUS MEDICAL CARE AG & CO KGAA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €68.35, then €65.59. Passing €86.00 would question the continuation of the fall.

Valérie GASTALDY

Analyse court terme - FRESENIUS MEDICAL CARE AG & CO KGAA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 68,35 €, puis 65,59 €. Le franchissement de 86,00 € remettrait en cause la suite de la baisse.

Valérie GASTALDY

Short term view - FRESENIUS MEDICAL CARE AG & CO KGAA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €68.35, then €65.59. Passing €86.00 would question the continuation of the fall.

Jérôme VINERIER

Analyse moyen terme - FRESENIUS MEDICAL CARE AG & CO KGAA : La tendance est baissière.

La tendance est baissière. Le mouvement se poursuit. Le prochain objectif est à 68,90 €, puis 61,20 €. Le franchissement de 91,60 € remettrait en cause la suite de la baisse.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch